As expected, responsive tumor types exhibited an increased tumor mutation burden (TMB), elevated immune checkpoint expression, more CD8+ T cells, and increased cytolytic activity (Additional file 1: Fig. S8c) [40]. This evidence concerns the gene CD8A and neoplasm.